Other

Merck + Co., Inc.

Eliza Nor Biopharmaceuticals, Inc.

John F Hartmann

Dan A Farcasiu

Ferenc J Sztaricskai

Pal Herczegh

Janos Borbely

Magdolna Bodnar

Jozsef Kollar

Arpad Kovacs

Gyorgy Vamosi

Istvan Hajdu

Miklos Hornyak

Macromolecular contrast agents for magnetic resonance imaging are described. Biomolecules and their modified derivatives form stable complexes with paramagnetic ions thus increasing the molecular relaxivity of carriers. The synthesis of biomolecular based nanodevices for targeted delivery of MRI contrast agents are described. Nanoparticles (NP) have been constructed by self-assembling of chitosan (CHIT) as polycation and poly-gamma glutamic acids (PGA) as polyanion. NP's are capable of Gd-ion uptake forming a particle with suitable molecular relaxivity. Folic acid (FA) is linked to the NP's to produce NP-FA bioconjugates that can be used for targeted in vitro delivery to a human cancer cell line.

Cancer cell diagnosis by targeting delivery of nanodevices

Compounds having utility in achieving the foregoing objects of the invention are prepared by reacting a 2,2-bis-(disubstituted-phosphoryl)-ethylsulfanyl-acetic acid compound with a pharmaceutically active chemical entity effective to treat the underlying disease state or with non-pharmaceutical entities such as pesticides, insecticides, fungicides or poisons for vermin.

Therapeutic derivatives of diphosphonates

An object of the present invention is to provide a non-invasive method to detect H. pylori within the stomach and duodenum. Another object is to provide a non-invasive method to localize this organism within the stomach and duodenum. A further object is to provide a kit containing the reagents for carrying out the diagnostic assay of the present invention.

Diagnostic assay for localizing H. pylori

The present invention is directed to compositions, methods and kits for treating areas of H. pylori infection in the GI tract. The active ingredient is an antibiotic-bisphosphonate adduct wherein the antibiotic is selected for its ability to eradicate H. pylori. Other components include a salt of a divalent cation that is insolubilized in vivo at alkaline pH, and optionally a substrate from which the enzyme urease liberates NH.sub.3.

Monotherapy of peptic ulcers and gastritis

Novel chemotherapeutic agents having utility in treating infectious diseases such as periodontal disease, certain urinary tract infections, and infectious urinary tract stones, are obtained by combining chemically a diphosphonate compound with a therapeutic agent effective against the foregoing diseases.

Therapeutic derivations of diphosphonates

Novel chemotherapeutic agents having utility in treating infectious diseases such as periodontal disease, certain urinary tract infections, infectious urinary tract stones, and bone cancer, are obtained by combining chemically a diphosphonate compound with a therapeutic agent effective against the foregoing diseases.

Process and compositions for lowering blood pressure in diabetic by employing a cyclopeptide compound is described.

Growing community of inventors

Princeton Junction, NJ, United States of America

John F Hartmann